Evaluating BPH: Is Transrectal Ultrasound Safe for Prostate Cancer Screening? - Urology

More Info

---

When evaluating benign prostatic hyperplasia (BPH) and the potential risk of prostate cancer, transrectal ultrasound (TRUS) can be a useful diagnostic tool. However, the safety and appropriateness of this procedure depend on various factors, especially considering the patient's overall health and medical history.

In your father's case, he is a 73-year-old male with a history of hypertension and diabetes, which are important considerations when evaluating any medical procedure. His recent PSA levels have shown fluctuations, with values reaching as high as 15 after a digital rectal exam (DRE). This elevation in PSA, combined with his symptoms of nocturia and frequency, raises the question of whether further investigation for prostate cancer is warranted.

Transrectal ultrasound is generally considered safe and is commonly used to visualize the prostate gland. It can help in assessing the size of the prostate, identifying any abnormalities, and guiding biopsies if necessary. The procedure is minimally invasive and typically performed under local anesthesia, which reduces discomfort. However, there are some risks associated with TRUS, including infection, bleeding, and discomfort during the procedure. Given your father's age and existing health conditions, these risks should be carefully weighed against the potential benefits of the procedure.

In terms of prostate cancer screening, the PSA test is a critical component. While a PSA level of 10-15 ng/mL is concerning, it is essential to interpret these results in the context of other clinical findings. The Gleason score, which assesses the aggressiveness of prostate cancer, is also crucial. In your father's case, if he has a Gleason score of 6, this indicates a low to moderate risk of cancer. However, the presence of atypical glands or other concerning features in previous biopsies may necessitate further investigation.

If TRUS is performed, it can provide valuable information about the prostate's structure and help determine if a biopsy is needed. However, if your father's health status poses significant risks for complications, it may be prudent to consider alternative approaches. For instance, active surveillance could be an option if the cancer is low-risk and not causing significant symptoms. This involves regular monitoring of PSA levels, DREs, and possibly repeat biopsies without immediate intervention.

Additionally, discussing the potential for other imaging studies, such as MRI, could provide more detailed information about the prostate and help assess the risk of cancer without the need for a TRUS. MRI can be particularly useful in identifying suspicious lesions that may warrant a biopsy.

Ultimately, the decision to proceed with TRUS or any further testing should involve a thorough discussion between your father and his healthcare provider. Factors such as his overall health, the potential risks of the procedure, and the implications of the findings should all be considered. It is essential to have a clear understanding of the goals of the investigation and the possible outcomes, including the management options available if prostate cancer is diagnosed.

In summary, while TRUS is a safe and effective tool for evaluating prostate health, it is crucial to consider your father's unique medical history and current health status. Engaging in a detailed conversation with his healthcare team will help determine the most appropriate course of action for his situation.